169 Markers of Bacterial Translocation in Patients With Chronic Liver Disease

G A A b st ra ct s for HE-related, and all-cause hospitalizations were 0.21 and 0.45 with long term rifaximin use; both rates were significantly lower (p<0.0001, p=0.0051) compared to the corresponding rates for RCT placebo (0.72, 1.31). Safety was not adversely impacted with increased long term rifaximin exposure. Adverse event rates and the rate of change in the mean MELD scores remained stable in the long term. Mortality rates with long term rifaximin exposure were similar between all rifaximin patients (0.1) and the RCT placebo group (0.2) . Conclusions: Long term treatment with rifaximin 550 mg BID afforded continued protection from HE, reduced the hospitalization rate, and did not adversely affect safety or mortality in patients with cirrhosis.